Stephenson Pamela's Form 4/A amendment
AmendedAlbireo Pharma, Inc. (ALBO) · filed Jan 9, 2023
- Accession no.
- 0001209191-23-002635
- Filed
- Jan 9, 2023
- Trade date
- Jul 22, 2022
- Filing delay
- 171 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jul 25, 2022
This filing lists 1 non-derivative transaction. Open-market sales total $2.62K. It was filed 171 days after the trade.
This amendment replaces 0001209191-22-043102 (filed Jul 25, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stephenson PamelaCIK 0001767650 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 22, 2022 | Common Stock | SSaleDisposed | −106 | $24.67F2 | −$2,615.02 | 45,649 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Referenced by the price of 1 transaction in Table I.
- F3
Represents 15,923 shares of common stock and 29,726 restricted stock units.
Remarks
This amended Form 4 is being filed solely to correct the numbers of shares disclosed in column 5 of Table I and footnote 3, as the reporting person did not acquire 547 shares of common stock under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.